glucosidases. Both in vitro and in vivo testing in animal models (see publications below) of different infections and inflammation confirmed radioactivity accumulation only in live pathogenic fungi. Imaging with [18F]-FCB in mice infected with Aspergillus, for example, showed that the imaging agent can detect whether there has been a response to antifungal therapy. One major advantage is that synthesis of [18F]-FCB is simple and efficient using readily commercially available reagents. The radiolabeled agent can then be administered intravenously, and imaging performed 90-120 minutes after injection. A radiosynthesis kit has also been developed and can be used at ambient temperature to produce [18F]-FCB from a commercially acquired kit in less than two hours without the need for a cyclotron.

Potential Commercial Applications

Imaging of live infections.

#### Development Stage

- In vitro data
- Preclinical in vivo data (mouse models)

#### Related Publications

- Zhang X, Basuli F, Shi Z–D, Shah S, Shi J, Mitchell A, Lai J, Wang Z, Hammoud DA, Swenson RE. Synthesis and Evaluation of Fluorine-18-Labeled L-Rhamnose Derivatives. Molecules. 2023; 28(9):3773. https://doi.org/10.3390/molecules28093773.
- Shah, S., Lai, J., Basuli, F.,
  Martinez-Orengo, N., Patel, R., Turner,
  M.L., Wang, B., Shi, Z.D., Sourabh, S.,
  Peiravi, M., Lyndaker, A., Liu, S.,
  Seyedmousavi, S., Williamson, P.R.,
  Swenson, R.E., & Hammoud, D.A.
  (2024). Development and preclinical
  validation of 2-deoxy 2[18F]fluorocellobiose as an Aspergillusspecific PET tracer. Science
  translational medicine, 16(760),
  eadl5934. https://doi.org/10.1126/
  scitranslmed.adl5934.
- Basuli, F., Shi, J., Shah, S., Lai, J., Hammoud, D.A., & Swenson, R.E. (2024). Fully Automated Cassette-Based Synthesis of 2-Deoxy-2-

[18F]Fluorocellobiose Using Trasis AllInOne Module. Journal of labelled compounds & radiopharmaceuticals, 67(9), 308–313. https://doi.org/10.1002/ jlcr.4116.

#### Intellectual Property

- NIH Reference No. E–163–2019; U.S. Provisional Patent Application 62/882,023 filed August 2, 2019; International Patent Application PCT/US2020/044446 filed July 31, 2020 (published as WIPO publication WO 2021/025984); and national stage patent applications filed in Europe (20757180.3) and the United States (17/631.600).
- NIH Reference No. E-080-2023; U.S. Provisional Patent Application 63/492,302 filed March 27, 2023, and International Patent Application PCT/US2024/021440 filed March 26, 2024.

Dated: August 28, 2024.

#### Michael A. Shmilovich,

Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

[FR Doc. 2024–19719 Filed 9–3–24; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Administration for Strategic Preparedness and Response

# Statement of Organization, Functions, and Delegations of Authority

**AGENCY:** Administration for Strategic Preparedness and Response, HHS. **ACTION:** Notice.

SUMMARY: This notice announces revisions to the organizations within the Administration for Strategic Preparedness and Response (ASPR).

DATES: These revisions were approved by the Administrator and Assistant Secretary of ASPR on July 2, 2024, and became effective on July 2, 2024.

SUPPLEMENTARY INFORMATION: Part A, Office of the Secretary, Statement of

Organization, Functions, and

Delegations of Authority of the U.S. Department of Health and Human Services (HHS) is being amended at Chapter AN, Office of the Assistant Secretary for Preparedness and Response (ASPR), as last amended at 88 FR 10125 (Feb. 16, 2023), 85 FR 8302 (Feb. 13, 2020), 83 FR 33941 (July 18, 2018), 79 FR 70.535 (Nov. 26, 2014), 78 FR 25277 (April 30, 2013), 78 FR 7784 (Feb. 4, 2013), 75 FR 35.035 (June 21, 2010) to refine the functions within ASPR to more closely align with ASPR's Operating Division status and expansion of mission which includes preparing for and responding to ever-increasing manmade and naturally occurring threats which have the potential to degrade public health, access to healthcare, access to emergency medical services, and national security.

In 2023, ASPR underwent a major reorganization that was designed to recognize the Agency's expanded scope of work as a new Operating Division, simplify the organizational structure, provide greater role clarity, and increase collaboration across teams. These changes were targeted in nature and focused on areas where the mission had recently expanded. Since the implementation of ASPR's 2023 reorganization, the Agency has undergone additional, modest adjustments to its organizational structure to better clarify missions, roles, and responsibilities at the Deputy Assistant Secretary (DAS)-level, Officelevel, and Division level. Substantive changes to ASPR organizations are noted below. The changes are as follows:

Global Change: Naming Conventions for ASPR Components

To more closely align with the maturation of ASPR's Operating Division status and mission of the organization, the titles for the ASPR component overseen by an ASPR Deputy Assistant Secretary (DAS) are now called "Centers" instead of "Offices." The chart below provides the previous title and the new title.

Previous title	New title
Immediate Office of the ASPR Office of Administration Office of Preparedness Office of Response Office of Biomedical Advanced Research Development Authority Office of HHS Coordination, Operations, and Response Element Office of Industrial Base Management and Supply Chain Office of the Strategic National Stockpile	Center for Response. Center for the Biomedical Advanced Research Development Authority.

The following organizational updates by Center are modifications from the Agency's 2023 reorganization. All other organizational structure remains as previously noticed in the 2023 **Federal Register** Notice.

#### **Center for Administration**

- New Office: Office of Facilities Management
- Office Name Change: Update Office of Human Capital to Office of Human Resources

#### Center for Preparedness

- Office Name Change: Update Office of Security and Intelligence to Office of Security, Vetting, and Protection
- Office Name Change: Update the Office of Information Management, Data, and Analytics to Office of Data, Analytics, and Information Advantage

# Center for Industrial Base Management and Supply Chain

- Office Name Change: Update Office of Personal Protective Equipment and Durable Medical Equipment to Office of Critical Medical Equipment
- Office Name Change: Update Office of Advanced Manufacturing Technologies to the Office of Enabling Innovations and Technologies

### Center for the HHS Coordination Operations and Response Element

In 2022, the Secretary of HHS transitioned the DOD–HHS partnership that was formerly called Operation Warp Speed into ASPR as the HHS Coordination and Operations Response Element or H–CORE. Moving H–CORE fully into ASPR provided ASPR with sole responsibility for the development, manufacture, and distribution of the nation's COVID–19 vaccines and therapeutics.

H-CORE reports to the Administrator and Assistant Secretary for Preparedness and Response (the ASPR) and works in partnership with other entities across ASPR, such as the Center for the Biomedical Advanced Research and Development Authority (BARDA), the Center for the Strategic National Stockpile (SNS), and the Center for Industrial Base Management and Supply Chain (IBMSC), to deploy vaccines, therapeutics, and other medical countermeasures products and supplies to the American public during infectious disease outbreaks and other public health emergencies. H-CORE coordinates and accelerates the logistics readiness and operations in response to infectious diseases, public health emergencies, and disasters in support of the ASPR.

H–CORE is headed by a Deputy Assistant Secretary and includes the following components:

- Office Name Change: Update from Office of Analytics to *Office of Analytics, Data, and IT*
- Office Name Change: Update from Office of Plans to Office of Planning and Operational Coordination
- Office of Supply, Production, and Distribution
- New Office: Office of Infectious Disease Response
- Delete Office: Office of Security and Assurance
- Delete Office: Office of Vaccine Development Coordination
- Delete Office: Office of Therapeutics Development Coordination

I. Delegations of Authority: All delegations and redelegations of authority made to officials and employees of affected organizational components will endure pending further redelegation, provided they are consistent with this reorganization.

All updates herein supersede any prior directives pertaining to the establishment of Agency components, including but not limited to directives pertaining to the establishment of H—CORE.

The Administrator and Assistant Secretary for Preparedness and Response of ASPR, Dawn O'Connell, having reviewed and approved this document, authorizes Adam DeVore, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the **Federal Register**.

### Adam DeVore,

Federal Register Liaison, Administration for Strategic Preparedness and Response. [FR Doc. 2024–19809 Filed 9–3–24; 8:45 am]

BILLING CODE 4150-37-P

## DEPARTMENT OF HOMELAND SECURITY

### **Coast Guard**

[Docket No. USCG-2024-0739]

Information Collection Request to Office of Management and Budget; OMB Control Number: 1625–0113

**AGENCY:** Coast Guard, DHS. **ACTION:** Sixty-day notice requesting comments.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an extension of its approval for the following collection of information: 1625–0113, Crewmember Identification Documents; without change. Our ICR describes the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below.

DATES: Comments must reach the Coast Guard on or before November 4, 2024.

ADDRESSES: You may submit comments identified by Coast Guard docket number [USCG—2024—0739] to the Coast Guard using the Federal eRulemaking Portal at <a href="https://www.regulations.gov">https://www.regulations.gov</a>. See the "Public participation and request for comments" portion of the SUPPLEMENTARY INFORMATION section for further instructions on submitting comments.

A copy of the ICR is available through the docket on the internet at https://www.regulations.gov. Additionally, copies are available from: Commandant (CG-6P), Attn: Paperwork Reduction Act Manager, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE, Stop 7710, Washington, DC 20593-7710.

FOR FURTHER INFORMATION CONTACT: A.L. Craig, Office of Privacy Management, telephone 202–475–3528, fax 202–372–8405, or email hqs-dg-m-cg-61-pii@uscg.mil for questions on these documents.

## SUPPLEMENTARY INFORMATION:

## Public Participation and Request for Comments

This notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. 3501 et seq., chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection's purpose, the Collection's likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection.

The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) the practical utility of the Collection; (2) the accuracy of the estimated burden of the Collection; (3) ways to enhance the quality, utility, and clarity of information subject to the Collection; and (4) ways to minimize the burden of the Collection on respondents,